YEONG-MIN PARK

PROFESSOR

DEPT. OF IMMUNOLOGY,
SCHOOL OF MEDICINE

e-mail: immun3023@kku.ac.kr

Educations

1986 M.D., Chonbuk National University, Jeonju, Korea
1988 M.S., Chonbuk National University, Jeonju, Korea
1991 Ph.D., Chonbuk National University, Jeonju, Korea

Professional Background

2015-Present President: The Korean Association of Immunologists(KAI)
2013-Present Professor: School of Medicine, Konkuk University
2013-2015 Head of Division of Medical sciences: National Research Foundation of Korea(NRF)
2014 Vice President: The Korean Vaccine society
2014 Vice-organizer: 12th international Symposium on Dendritic cells
2012- 2013 Chair Scientific Committee: Korean society for Biochemistry and Molecular Biology(KSBMB)
1995-2013 Assistant Professor: Associate Professor, Professor School of Medicine Pusan National University
1998-2000 Research Associate Scientist: School of Medicine Yale University in U.S

Top 5 Publications

- Kim JS, Cha SH, Kim WS, Han SJ, Cha SB, Kim HM, Kwon KW, Kim SJ, Choi HH, Lee J, Cho SN, Koh WJ, **Park YM**, Shin SJ. A Novel Therapeutic Approach using Mesenchymal Stem Cells to Protect against Mycobacterium abscessus. Stem Cells. 2016(In press) (Corresponding authors)
- Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, **Park YM**, Lee JW. Linalool-incorporated nanoparticles as a novel anticancer agent for epithelial ovarian carcinoma. Mol Cancer Ther. 2016(In press) (Corresponding authors)
- Kang TH, Kim YS, Kim S, Yang B, Lee JJ, Lee HJ, Lee J, Jung ID, Han HD, Lee SH, Koh SS, Wu TC, **Park YM**. Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4. Oncotarget. 2015 Sep 29;6(29):27751-62(Corresponding authors)
- Kim SY, Heo MB, Hwang GS, Jung Y, Choi do Y, **Park YM**, Lim YT. Multivalent Polymer Nanocomplex Targeting Endosomal Receptor of Immune Cells for Enhanced Antitumor and Systemic Memory Response. Angew Chem Int Ed Engl. 2015 Jul 6;54(28):8139-43 (Corresponding authors)
- Jung ID, Jeong SK, Lee CM, Noh KT, Heo DR, Shin YK, Yun CH, Koh WJ, Akira S, Whang J, Kim HJ, Park WS, Shin SJ, **Park YM**. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Research 2011 Apr 15; 71(8):2858-70(Corresponding author)

RESEARCH INTERESTS

1. Sepsis Treatment



Sepsis, the systemic inflammatory response syndrome caused by serious infection, is a life-threatening condition worldwide. Sepsis includes the cytokine storm that induces whole-body inflammation and multiorgan failure. Many researchers have devised strategies to reduce tissue damage in sepsis patients. Examples include blocking TNF receptor and IL-1 receptor on immune cells; inhibiting pathophysiological events such as aberrant blood clotting; blocking TLR signals by PAMPs; and neutralizing PAMPs. More recently, we have studied the development of a new-generation antibiotic that blocks the lipopolysaccharide (LPS)-mediated cytokine storm, thereby preventing multi-organ failure.

2. Development of New Cancer Immunotherapies



- DC-based cancer immunotherapy using novel adjuvants
- Development of tumor targeting and immunotherapeutic agents, focusing on changes in the tumor microenvironment following anti-cancer drug treatment

3. Targeted Gene Silencing Using Nanoparticles in Ovarian Carcinoma



RNA interference (RNAi)-based approaches possess great potential for cancer therapy. SiRNA-based therapy may allow the development of a broad armamentarium of targeted drugs against genes that are difficult to target with traditional approaches such as small molecules or monoclonal antibodies. However, one of the key challenges in the use of siRNAs for therapy is obtaining efficient intracellular delivery, because unprotected siRNA is rapidly cleared or degraded by nucleases. In the current study, we demonstrate the highly selective delivery of targeted nanoparticles to αvβ3 integrin-expressing cells and the therapeutic efficacy of this approach in multiple ovarian cancer models.